Dataset Information

The value of circulating lymphocytic subpopulations in the diagnosis and repair of ischemic stroke patients with dizziness.

ABSTRACT:

Background

To determine whether dizziness can contribute to stroke as a main cause still remains challenging. This study aims to explore clinical biomarkers in the identification of ischemic stroke patients from people with dizziness and the prediction of their long-term recovery.

Methods

From January 2018 to June 2019, 21 ischemic stroke patients with a main complaint of dizziness, 84 non-stroke dizziness patients and 87 healthy volunteers were recruited in this study. Then, their peripheral blood samples were collected, and the percentages of circulating lymphocytes T cells, CD4⁺ T cells, CD8⁺ T cells, T^-/- cells (DNTs), CD4⁺ regulatory T cells (Tregs), CD8⁺ Tregs, B cells and regulatory B cells (Bregs) were examined to identify biomarkers with clinical value.

Results

According to our data, a significant difference in the DNTs proportion was detected between non-stroke dizziness and ischemic stroke patients with dizziness (p = 0.0009). The Bregs proportion in ischemic stroke patients with dizziness was lower than that in non-stroke dizziness patients (p = 0.035). In addition, the percentage of Bregs and DNTs within lymphocytes in patients' peripheral blood exhibited a significant negative correlation with stroke occurrence (Bregs, p = 0.039; DNTs, p = 0.046). Moreover, the Bregs and DNTs within lymphocytes were negatively related to participants' age, while presented a weak relationship with clinical risks like smoking, hypertension, and diabetes. Then, area under the receiver operating characteristic curve (AUC) of Bregs and DNTs together was 0.768, the risk factors and Bregs or DNTs ranged from 0.795 and 0.792, respectively, and the AUC value of risk factors, Bregs and DNTs combination was further increased to 0.815. Furthermore, the Bregs percentage within lymphocytes at admission was also a potential predictor of repair at discharge and the following 3 months.

Conclusion

Bregs and DNTs could be the clinical biomarkers together in the identification of ischemic stroke patients from people with dizziness.

SUBMITTER: Wang Y

PROVIDER: S-EPMC9670111 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The value of circulating lymphocytic subpopulations in the diagnosis and repair of ischemic stroke patients with dizziness.

Wang Yong Y Huang Yichen Y Li Sicheng S Lin Jixian J Liu Yang Y Gao Yanqin Y Zhao Jing J

Frontiers in aging neuroscience 20221103

<h4>Background</h4>To determine whether dizziness can contribute to stroke as a main cause still remains challenging. This study aims to explore clinical biomarkers in the identification of ischemic stroke patients from people with dizziness and the prediction of their long-term recovery.<h4>Methods</h4>From January 2018 to June 2019, 21 ischemic stroke patients with a main complaint of dizziness, 84 non-stroke dizziness patients and 87 healthy volunteers were recruited in this study. Then, thei ...[more]

PMID: 36408111

Similar Datasets

Project description:Aim of the present study is to identify all circulating miRNAs that are modulated in patients with stroke, to select specific miRNAs to be used as disease biomarkers to improve both diagnosis and prognosis. Background. Stroke is the second-most common cause of death worldwide. The major factor limiting prognosis in patients affected by acute stroke is the very limited therapeutic window, so that most patients are not able receive the most successful treatments because of delays in diagnosis and to differentiate between ischemic and hemorrhagic etiology. Circulating levels of selected microRNAs (miRNAs) were found to be modulated both in animal experimental models and in patients with stroke, opening up new avenues for the identification of more effective and specific biomarkers to identify and risk-stratify stroke patients. Study aim. Aim of the present study is to identify all circulating miRNAs that are modulated in patients with stroke, to select specific miRNAs to be used as disease biomarkers to improve both diagnosis and prognosis. Methods. RNA was extracted from plasma samples using a commercial RNA extraction kit and quality of extracted material was assessed using a fluorometric electrophoretic assay (Agilent 4200 TapeStation, Santa Clara, CA, USA). MiRNA profiling was performed using the Affymetrix platform using GeneChip 4.0 (Thermo Fischer Scientific, Waltham, MA, USA). RT-PCR was performed using the Taqman protocol. MiRNA were chosen among those with the most relevant modulation between the groups. Results. Among the circulating miRNAs that were most down-regulated in stroke patients, we identified miR-3135b (20-fold, p<0.001), associated with vascular calcifications and heart failure; miR-1275 (18-fold, p=0.028), involved in cardiovascular atherosclerotic diseases and a sponge for circMAN2B2 in cancer; miR-4467 (13-fold, p=0.003), modulated in neurodegenerative diseases; and miR-7170 (7-fold, p<0.001). Among the circulating miRNAs that were most up-regulated in stroke patients, we identified miR-18a (35-fold, p=0.004), associated with stroke in the Framingham Cohort; the platelet-enriched miR-22-5p (24-fold, p=0.004), that is modulated in Huntington Disease; miR-199a (11-fold, p=0.012), a marker of brain microvascular injury and of stroke severity in rats, and miR-106b (10-fold, p=0.009), a regulator of neural stem-cell proliferation/differentiation whose level are modulated in patients with neurodegenerative diseases. Conclusions. Our results identified several circulating miRNAs that are down- of up-regulated in stroke patients. Among those with the most relevant differential expression, several miRNAs were identified that are known to play a role in the pathophysiology of neurovascular diseases, paving the way to a new class of smart pathophysiology-based biomarkers in stroke.

Project description:To provide insight into molecular diagnosis and individualized treatment of ischemic stroke (IS), several available datasets in IS were analyzed to identify the differentially expressed genes and microRNAs (miRNAs). Series matrix files from GSE22255 and GSE16561 (mRNA profiles), a well as GSE110993 (miRNA profile) were downloaded from the Gene Expression Omnibus database. System‑level clustering was performed with GeneCluster 3.0 software, and gene annotation and pathway enrichment were performed with gene ontology analysis and Database for Annotation, Visualization and Integrated Discovery software. For a protein‑protein interaction (PPI) network, Biological General Repository for Interaction Datasets and IntAct interaction information were integrated to determine the interaction of differentially expressed genes. The selected miRNA candidates were imported into the TargetScan, miRDB and miRecords databases for the prediction of target genes. The present study identified 128 upregulated and 231 downregulated genes in female stroke patients, and 604 upregulated and 337 downregulated genes in male stroke patients compared with sex‑ and age‑matched controls. The construction of a PPI network demonstrated that male stroke patients exhibited YWHAE, CUL3 and JUN as network center nodes, and in female patients CYLD, FOS and PIK3R1 interactions were the strongest. Notably, these interactions are mainly involved in immune inflammatory response, apoptosis and other biological pathways, such as blood coagulation. Female and male upregulated genes were cross‑validated with another set of Illumina HumanRef‑8 v3.0 expression beadchip (GSE16561). Functional item association networks, gene function networks and transcriptional regulatory networks were successfully constructed, and the relationships between miRNAs and target genes were successfully predicted. The present study identified a number of transcription factors, including DEFA1, PDK4, SDPR, TCN1 and MMP9, and miRNAs, including miRNA (miR)‑21, miR‑143/145, miR‑125‑5p and miR‑122, which may serve important roles in the development of cerebral stroke and may be important molecular indicators for the treatment of IS.

Project description:This was a case-control study conducted from August 2020 to January 2021, in which 9 ischemic stroke and 2 healthy individuals (healthy control group) attending the Guangdong Provincial People's Hospital were recruited for plasma exoLRs sequencing. The other 10 normal samples from a previous study published in the Gene Expression Omnibu (GEO) database (Accession No. GSE159657) were used as part of healthy control group to analyzed the expression profile together. 30 ischemic stroke patients and 30 healthy individuals were also recruited for validation of the expression of exoLRs. Ischemic stroke diagnosis was performed according to World Health Organization guidelines and validated using computed tomography or magnetic resonance imaging. The ischemic stroke must have lasted not more 48 hours prior to recruitment. The participants ranged between 18–75 years old and were from either gender. To be included in this study, healthy individuals had to have displayed normal renal and liver function, and with no history of smoking, malignancy, recent cardiovascular or cerebrovascular events, rheumatologic disorders, chronic heart failure, diabetes, acute or chronic infectious disease, aortic dissection, pulmonary embolism, myocarditis, pericarditis or congenital heart disease.Blood samples were collected immediately at admission before thrombolytic therapy. For each patient, 2 ml of venous blood was collected in ethylene diamine tetraacetic acid routine blood tubes. In order to extract plasma, the blood was centrifuged at 3000×g for 10 min at 4 °C and the supernatant was carefully transferred to a new tube for repeated centrifugation. Then the plasma was stored in cryogenic vials at −80 °C till further use. Total RNA in exosomal vesicles was extracted using the exoRNeasy Serum/Plasma kit (Qiagen), following the manufacturer’s protocol. The RNA-seq libraries were constructed using SMART technology (Clontech). RNA sequencing was performed by the illumine Nova-Seq 6000 System.

Dataset Information

The value of circulating lymphocytic subpopulations in the diagnosis and repair of ischemic stroke patients with dizziness.

Background

Methods

Results

Conclusion

Publications

The value of circulating lymphocytic subpopulations in the diagnosis and repair of ischemic stroke patients with dizziness.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets